·
Pulse duration of 0.1-1.0 ms
·
Frequency between 30 and 100 Hz
·
Can be uniphasic or biphasic (Low & Reed, 2000)
·
Usually asymmetrical in nature (Figure 3)
o
Positive portion has a short duration and a high
amplitude
o
Negative portion has a long duration and low amplitude (Knight &
Draper, 2008)
Figure 3: An example of a faradic waveform |
·
Pulse duration of 0.5-1.5 seconds
·
Intensity of 10 to 390 Volts (Products, 2002)
With the
transeva able to reach 390 Volts and a skin resistance of as low as 1000 Ohms
if the skin is moist or broken; according to Ohms law (V=IR), the current
applied to the skin is 390 mA (U.S. Department of Health and Human Services,
1998). With the use of our calculations, there is potential to exceed the sensory current for humans (5mA) and may cause tissue
damage and ventricular fibrillation (fibrillation threshold 300-500 mA)
(Ferris, 2005). This suggests that the transeva may have safety concerns.
With a pulse
duration more than 1000 times the duration of conventional faradism. Is the
Winks Greene Transeva truly based on faradic principles?
No other
specifications regarding the transeva have been acknowledged on the
manufacturer’s website (Products,
2002). Without further information, the way in which the Winks Greene Transeva
works is unable to be determined. Furthermore, there is no evidence showing Winks Greene Transeva has safety issues, despite having no information to prove otherwise.
Today,
faradism is not a major component of therapeutic electrical stimulation in
clinical practice. There are other types of electrical stimulation, transcutaneous electrical nerve stimulation
(TENS), which have been proven to be safe and TGA approved (Jones & Johnson, 2009).
References
Jones,
I & Johnson, M. (2009). Transcutaneous Electrical Nerve Stimulation. Continuing
Education
in Anaesthesia, Critical Care & Plan, 9(4), 130-135. doi: 10.1093/biaceaccp/mkp021
Ferris, C. (2005). Safety. In J.
Whitaker (2nd ed.), The Electronics
Handbook (pp. 2317
2342). Boca Raton, USA: CRC Press.Knight, K. L., & Draper, D. O. (2008). Therapeutic Modalities: The Art & Science. Baltimore,
USA: Lippincott Williams & Wilkins.
Low, J., & Reed, A. (2000). Electrotherapy Explained:
Principles & Practice (3rd ed.).
Oxford, UK: Butterworth Heinemann.
Scott, O. (2002). Sensory and Motor Nerve Activation. In S.
Kitchen, Electrotherapy:
Evidence-Based Practice (pp. 57-73). Edinburgh, UK: Churchill Livingstone.
U.S. Department of Health and Human
Services. (1998). Worker Deaths By
Electrocution
(NIOSH Publication No. 98-131).
Atlanta, USA: Casini, V.
Winks
Greene Transeva: Products. (2002).
Retrieved March 26, 2012, from
http://www.winksgreenetranseva.com/Products/products.html
Overall your message is appropriate and presents the aspects that I directed you to explore. Please be careful about writing such damming prose in a globally public forum. Much more accurate to write e.g. "Our calculations indicate that the transeva potentially has issues with safety." rather than 'proves' and 'faults'. However, your points are otherwise well made and give Australians a picture of the present state of affairs. Again some softer language is required - we never intend to hurt the feelings of people in South Africa and Europe who use the device effectively and with few problems. It would be wise to acknowledge that you have neither found evidence of harm from this device nor actually made contact with any clinicians who are using it, in a subsequent post. I love my job! CY
ReplyDelete